Loading news...
Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) insider Derek Maetzold sold 4,017 shares of the stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $40.01, for a total transaction of $160,720.17. Following the sale, the insider owned 87,715 shares in the company, valued at
Does Castle Biosciences, Inc. (CSTL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Campbell and CO Investment Adviser LLC bought a new stake in shares of Castle Biosciences, Inc. (NASDAQ: CSTL) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 26,996 shares of the company's stock, valued at approximately $615,000. Campbell and CO Investment Adviser LLC
2025 total revenue expected to exceed $340 million, above the previously guided range of $327-335 million 2025 total test reports for our core revenue drivers (DecisionDx ® -Melanoma, TissueCypher ® ) increased 37% over 2024 Year-end 2025 cash, cash equivalents and marketable investment securities expected to be approximately $300 million FRIENDSWOOD, Texas, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended Dec. 31, 2025. “We are extremely pleased with our excellent fourth quarter and full year preliminary results, which reflect both the strength of our innovative test portfolio and the dedication of the entire Castle team,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.
Shares of Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the eight ratings firms that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on
Castle Biosciences surged 77.9% after a Zacks upgrade, highlighting how the firm's stock picks outpaced the broader market in recent months.
Castle Biosciences (CSTL) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) shares hit a new 52-week high during trading on Monday after Canaccord Genuity Group raised their price target on the stock from $37.00 to $50.00. Canaccord Genuity Group currently has a buy rating on the stock. Castle Biosciences traded as high as $42.00 and last traded at
Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) insider Derek Maetzold sold 509 shares of the business's stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $40.04, for a total transaction of $20,380.36. Following the completion of the transaction, the insider owned 34,360 shares in
FRIENDSWOOD, Texas, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 15, 2025, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 83 employees covering an aggregate of 139,494 shares of common stock as an inducement material to their entering into employment with Castle Biosciences. The RSUs were granted pursuant to the Company's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
FRIENDSWOOD, Texas, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the largest prospective, multicenter study to date comparing next-generation sequencing (NGS)-based gene mutation analysis with the combination of DecisionDx-UM and Preferentially Expressed Antigen in Melanoma (PRAME) gene expression for predicting outcomes in patients with uveal melanoma (UM). The study, titled “Early Genetic Evolution of Driver Mutations in Uveal Melanoma,” was conducted by the Collaborative Ocular Oncology Group (COOG) and recently published in Nature Communications.
Castle Biosciences, Inc. (NASDAQ: CSTL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the nine ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a buy recommendation and one has given a strong buy
FRIENDSWOOD, Texas, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new systematic review and meta-analysis (SRMA) demonstrating that the TissueCypher® Barrett's Esophagus test provides clinically validated risk stratification for patients with Barrett's esophagus (BE). The findings confirm that TissueCypher can outperform traditional pathology or clinical factors alone to identify patients at increased risk of developing esophageal cancer.
Here is how Cronos Group (CRON) and Castle Biosciences, Inc. (CSTL) have performed compared to their sector so far this year.
FRIENDSWOOD, Texas, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of an independent expert consensus paper titled “31-Gene Expression Profiling for Cutaneous Melanoma: An Expert Consensus Panel,” which endorses the Company's DecisionDx-Melanoma test. The paper can be viewed here.1 “This consensus translates the robust data supporting DecisionDx-Melanoma into practical direction for clinicians,” said Derek Maetzold, president and chief executive officer of Castle Biosciences.
Castle Biosciences (CSTL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Castle Biosciences (CSTL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
CSTL, IDN, PANL, FSRL and PRM are showing sharp price strength amid renewed Wall Street volatility.
FRIENDSWOOD, Texas, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been recognized by the Houston Chronicle as a Houston Top Workplace, which celebrates people-focused, standout workplace cultures. This marks the fifth consecutive year the Company has been ranked among the Houston metro area's esteemed workplaces.
Four rising cash-flow stocks, including PRM, TILE, CSTL and GLDD, stand out with upgraded earnings estimates and strong VGM scores.